TY - JOUR
T1 - Old age and intense chemotherapy exacerbate negative prognostic impact of postoperative complication on survival in patients with esophageal cancer who received neoadjuvant therapy
T2 - a nationwide study from 85 Japanese esophageal centers
AU - Matsuda, Satoru
AU - Kitagawa, Yuko
AU - Okui, Jun
AU - Okamura, Akihiko
AU - Kawakubo, Hirofumi
AU - Takemura, Ryo
AU - Muto, Manabu
AU - Kakeji, Yoshihiro
AU - Takeuchi, Hiroya
AU - Watanabe, Masayuki
AU - Doki, Yuichiro
N1 - Funding Information:
We sincerely appreciate all the partici pating investigators for their valuable assistance with data collection: Sohei Matsumoto (Nara Medical University); Katsushi Takebayashi (Shiga University); Tomokazu Kakishita (Shikoku Cancer Center); Youichi Kumagai (Saitama Medical University); Takahisa Suzuki (Kure Medical Center and Chugoku Cancer Center); Yasuyuki Kawachi (Nagaoka Chuo General Hospital); Yasuhiro Tsubosa (Shizuoka Cancer Center Hospital); Naoya Yoshida (Kumamoto University); Yusuke Sato (Akita University); Noriaki Sadanaga (Saiseikai Fukuoka General Hospital); Tomoyuki Matsunaga (Tottori University); Masahiko Koike (Nagoya University); Kentaro Kishi (Osaka Police Hospital); Fumihiko Kato (International University of Health and Welfare); Hiroaki Nagano (Yamaguchi University); Shirou Kuwabara (Niigata City General Hospital); Takahiro Yoshida (Tokushima University); Katsunori Nishikawa (The Jikei University); Koichi Okamoto (Kanazawa University); Yoshihiko Kawaguchi (University of Yamanashi); Shinsuke Sato (Shizuoka General Hospital); Hironori Ohdaira (International University of Health and Welfare Hospital); Koji Kono (Fukushima Medical University); Akihiro Hoshino (Tokyo Medical and Dental University); Yousuke Kubota (Hiraka General Hospital); Sanshiro Kawata (Hamamatsu University); Takayoshi Kishino (Kagawa University); Yoshihiro Tanaka (Gifu University); Shuji Takiguchi (Nagoya City University Hospital); Fumihiro Yoshimura (Fukuoka University); Takeo Bamba (Niigata Cancer Center Hospital); Akio Kaito (Tsuchiura Kyodo General Hospital); Shinichi Kadoya (Ishikawa Prefectural Central Hospital); Yoshinori Hosoya (Jichi Medical University); Takuji Sato (Kochi Health Sciences Center); Makoto Kobayashi (Hakodate Goryoukaku Hospital); Kentaro Iwaki (Oita Red Cross Hospital); Gousuke Takiguchi (Kobe University); Motohisa Hagiwara (Nihonkai General Hospital); Koichi Ono (Obihiro Kosei Hospital); Ryuichiro Ohashi (Kagawa Prefecural Central Hospital); Shunichi Okushiba (Tonan Hospital); Takashi Nomura (Yamagata Prefectural Central Hospital); Yoichi Hamai (Hiroshima University); Eigo Otsuji (Kyoto Prefectural University); Koichi Demura (JCHO Osaka Hospital); Koichi Ogawa (University of Tsukuba); Yusuke Umeki (Fujita Health University); Dai Otsubo (Hyogo Cancer Center); Naoki Mori (Kurume University); Takashi Fukuda (Saitama Cancer Center); Tomohisa Egawa (Saiseikai Yokohamashi Tobu Hospital); Ken Sasaki (Kagoshima University); Shota Maruyama (Hachinohe City Hospital); Hisayuki Matsushita (Tochigi Cancer Center); Syoji Takagi (Okayama Red Cross Hospital); Takuo Takehana (Saku Central Hospital Advanced Care Center); Kotaro Yamashita (Osaka University); Tatsusi Suwa (Kashiwa Kousei General Hospital); Takushi Yasuda (Kindai University); Sang-Woong LEE (Osaka Medical and Pharmaceutical University); Nobutoshi Hagiwara (Nippon Medical School); Hirokazu Noshiro (Saga University); Shigeru Tsunoda (Kyoto University Hospital); Yukinori Kamio (Yamagata University); Hiroshi Ichikawa (Niigata University); Tomotaka Shibata (Oita University); Masaru Morita (Kyushu Cancer Center); Masanobu Nakajima (Dokkyo Medical University); Kazuhiro Noma (Okayama University); Shinya Mikami (St.Marianna University); Yusuke Taniyama (Tohoku University); Kiminari Naoshima (Iwate Prefectural Chubu Hospital); Ryo Maeyama (JCHO Kyushu Hospital); Yoshiro Aoki (Hiroshima City Asa Citizens Hospital); Hiroshi Miyata (Osaka International Cancer institute); Tomoki Yamatsuji (Kawasaki Medical School); Yoshihiro Ota (Tokyo Medical University Hospital); Yuji Akiyama (Iwate Medical University); Kazuo Koyanagi (Tokai University); Yuji Kikuchi (Tokyo Dental College Ichikawa General Hospital); Kazuhiko Yamada (National Center for Global Health and Medicine); and Takeo Fujita (National Cancer Center Hospital East). We also wish to extend our gratitude to Kumiko Motooka and Sanae Oikawa, staff of the study team, for their aid in collecting patient data.
Publisher Copyright:
© 2023, The Author(s) under exclusive licence to The Japan Esophageal Society.
PY - 2023/7
Y1 - 2023/7
N2 - Background: The prognostic impact of docetaxel, cisplatin, and 5-FU (DCF) reported in JCOG1109 was successfully validated using real-world data in patients < 75 years old. However, DCF was not reported to be beneficial in elderly patients with a relatively higher postoperative complication incidence. This study aimed to clarify the impact of postoperative complications on the prognosis of ESCC and the difference in the magnitude of the impact by age and regimen. Methods: Patients with esophageal squamous cell carcinoma (ESCC) who underwent subtotal esophagectomy at 85 authorized institutes were retrospectively reviewed from 2010 to 2015. The prognostic impact of postoperative anastomotic leakage (AL) and pneumonia on survival was evaluated. The prognostic value of the postoperative complications was assessed by stratifying patients according to age and neoadjuvant chemotherapy regimen. Results: Patients with AL, pneumonia, and infectious complications (ICs: a combination of pneumonia and AL) showed significantly worse overall survival (OS). IC served as a negative prognostic factor of OS and recurrence-free survival, and its negative prognostic impact was more evident in patients aged > 75 years. When the patients were further stratified by chemotherapeutic regimens, using the CF/IC(−) group as a reference, the DCF/IC (+) group showed significantly shorter OS in patients aged > 75 years with a hazard ratio (HR) of 2.551. The HR of the CF/IC (+) group was 1.503. Conclusions: The negative impact of postoperative complications on survival was confirmed in this nationwide study. Furthermore, its magnitude was higher in elderly patients who received triplet chemotherapy.
AB - Background: The prognostic impact of docetaxel, cisplatin, and 5-FU (DCF) reported in JCOG1109 was successfully validated using real-world data in patients < 75 years old. However, DCF was not reported to be beneficial in elderly patients with a relatively higher postoperative complication incidence. This study aimed to clarify the impact of postoperative complications on the prognosis of ESCC and the difference in the magnitude of the impact by age and regimen. Methods: Patients with esophageal squamous cell carcinoma (ESCC) who underwent subtotal esophagectomy at 85 authorized institutes were retrospectively reviewed from 2010 to 2015. The prognostic impact of postoperative anastomotic leakage (AL) and pneumonia on survival was evaluated. The prognostic value of the postoperative complications was assessed by stratifying patients according to age and neoadjuvant chemotherapy regimen. Results: Patients with AL, pneumonia, and infectious complications (ICs: a combination of pneumonia and AL) showed significantly worse overall survival (OS). IC served as a negative prognostic factor of OS and recurrence-free survival, and its negative prognostic impact was more evident in patients aged > 75 years. When the patients were further stratified by chemotherapeutic regimens, using the CF/IC(−) group as a reference, the DCF/IC (+) group showed significantly shorter OS in patients aged > 75 years with a hazard ratio (HR) of 2.551. The HR of the CF/IC (+) group was 1.503. Conclusions: The negative impact of postoperative complications on survival was confirmed in this nationwide study. Furthermore, its magnitude was higher in elderly patients who received triplet chemotherapy.
KW - Esophageal cancer
KW - Neoadjuvant chemotherapy
KW - Postoperative complications
UR - http://www.scopus.com/inward/record.url?scp=85146566923&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146566923&partnerID=8YFLogxK
U2 - 10.1007/s10388-022-00980-z
DO - 10.1007/s10388-022-00980-z
M3 - Article
C2 - 36662353
AN - SCOPUS:85146566923
SN - 1612-9059
VL - 20
SP - 445
EP - 454
JO - Esophagus
JF - Esophagus
IS - 3
ER -